SELLAS Life Sciences announced positive Phase 2a trial data for SLS009 (tambiciclib), a CDK9 inhibitor, combined with Brukinsa (zanubrutinib)...

PolarityBio’s SkinTE received Breakthrough Therapy Designation from the FDA for treating Wagner Grade 1 Diabetic Foot Ulcers (DFUs). This...

Nuwellis, Inc. announced updated findings from the AVOID-HF study, published in the Journal of the American College of Cardiology:...

In this interview, we engage with Dalton Signor, CEO at Miist Therapeutics, to explore their innovative inhaled therapies for...

Vaxxas, a clinical-stage biotech company, has completed enrollment for its Phase I clinical trial of an avian influenza A...

Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...

In this interview, we sat down with James Burt, CEO of Pharmanovia, to reflect on industry trends from 2024...

InnoCare Pharma received approval from China’s CDE to begin a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax),...

The FDA approved GSK’s PENMENVY, a combination vaccine against five serogroups of meningococcal disease (A, B, C, W, and...

Scientists in Cambridge developed a new prostate cancer test designed to revolutionize screening, diagnosis, and personalized treatment. The test...